P R O G R A M M E

Thursday 12 – Saturday 14 April, 2007 and Post-Conference Workshop, Sunday 15 April, 2007

The Institute of Child Health, Guilford Street, London WC1N
# Thursday 12 April 2007 – Molecular Nature of SE

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00</td>
<td><strong>Registration and Coffee</strong></td>
</tr>
</tbody>
</table>
| 9.00  | **Opening Address:**  
*Professor Roger Lemon, Director, UCL Institute of Neurology, London, UK*  
*Professor Peter Wolf, President, International League Against Epilepsy (ILAE), Copenhagen, Denmark* |
| 9.30  | **Morning Session: Neurochemistry and Brain Development**  
*Chair:*  
Professor Claude Wasterlain, Los Angeles, USA  
Professor Dimitri Kullmann, London, UK  
*On the Relevance of Prolonged Convulsive Status Epilepticus in Animals to the Etiology and Neurobiology of Human Temporal Lobe Epilepsy*  
Professor Robert Sloviter, Tucson, USA |
| 10.15 | **Changes in GABA<sub>A</sub> Receptors in Status Epilepticus**  
*Professor Guenther Sperk, Innsbruck, Austria* |
| 10.45 | **Impact of Receptor Changes on Treatment of Status Epilepticus**  
*Dr Jaideep Kapur, Charlottesville, USA* |
| 11.15 | **Tea**                                                              |
| 11.45 | **Inflammation Modifies Status Epilepticus-Induced Hippocampal Injury During Development**  
*Dr Raman Sankar, Los Angeles, USA* |
| 12.15 | **Influence of Brain Development on Status Epilepticus**  
*Professor Greg Holmes, Hanover, USA* |
| 12.45 | **Lunch (and Poster Presentations)**                                 |
| 14.00 | **Afternoon Session: Clinical and Experimental Neurogenetics**  
*Chair:*  
Professor Giuliani Avanzini, Milan, Italy  
Professor Solomon Moshe, New York, USA  
*Role of Genetic Influences in Animal Models of Status Epilepticus*  
*Dr Elyse Schauwecker, Los Angeles, USA* |
| 14.30 | **Role of Mitochondria in Status Epilepticus**  
*Dr Hannah Cock, London, UK* |
| 15.00 | **Tea**                                                              |
| 15.30 | **Gene and Protein Expression in Experimental Status Epilepticus**  
*Professor Asla Pitkänen, Kuopio, Finland* |
| 16.00 | **Status Epilepticus: the Past and the Future**  
*Professor Brian Meldrum, London, UK* |
| 16.30 | **Discussion/Summary**  
*Professor Claude Wasterlain, Los Angeles, USA*  
*Professor Dimitri Kullmann, London, UK*  
*Professor Giuliani Avanzini, Milan, Italy*  
*Professor Solomon Moshe, New York, USA* |
| 17.30 | **Close of Day One**                                                 |
## Friday 13 April 2007 – Clinical Aspects of SE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair/Professor/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.15</td>
<td>Registration and Coffee</td>
<td></td>
</tr>
</tbody>
</table>
| 8.30  | Morning Session: Nonconvulsive Status Epilepticus| Professor Fred Andermann, Montreal, Canada  
Professor Ilo Leppik, Minneapolis, USA |
| 8.45  | What is Nonconvulsive Status Epilepticus and What are its Subtypes? | Professor Simon Shorvon, London, UK |
| 9.15  | EEG Criteria for Nonconvulsive Status Epilepticus| Professor Peter Kaplan, Baltimore, USA |
| 9.45  | When is Epileptic Encephalopathy Nonconvulsive Status Epilepticus? | Dr Helen Cross, London, UK |
| 10.15 | How Urgent is the Treatment of Nonconvulsive Status Epilepticus? | Professor Pierre Thomas, Nice, France |
| 10.45 | Tea                                               |                                |
| 11.15 | UCB Satellite Symposium                          | Dr Matthew Walker, London, UK  
Professor Claude Wasterlain, Los Angeles, USA  
Dr Eugen Trinka, Innsbruck, Austria |
| 12.15 | Lunch                                            |                                |
| 12.15 | Afternoon Session: Treatment of Convulsive Status Epilepticus | Professor Emilio Perucca, Pavia, Italy  
Professor Jerome Engel, Los Angeles, USA |
| 13.30 | Clinical Pharmacology of Parenteral Use of Antiepileptic Drugs | Professor Meir Bialer, Jerusalem, Israel |
| 14.00 | The Use of Valproate and New Anti-Epileptic Drugs in Status Epilepticus | Dr Eugen Trinka, Innsbruck, Austria |
| 14.30 | Tea                                               |                                |
| 15.00 | Which Anaesthetics Should be Used in the Treatment of Refractery Status Epilepticus? | Dr Andrea Rossetti, Lausanne, Switzerland |
| 15.30 | Clinical Trial Design in Status Epilepticus: Problems and Solutions | Professor Brian Neville, London, UK |
| 16.00 | Intensive Care Unit Management of Patients with Status Epilepticus | Professor Thomas Bleck, Evanston, USA |
| 16.30 | The Surgical Treatment of Status Epilepticus      | Dr Samden Lhatoo, Bristol, UK  
continued |
17.00 Discussion
Professor Fred Andermann, Montreal, Canada,
Professor Ilo Leppik, Minneapolis, USA
Professor Emilio Perucca, Pavia, Italy
Professor Jerome Engel, Los Angeles, USA

18.00 Close of Day Two

Saturday 14 April 2007 – Outcomes of SE

8.30 Registration and Coffee

Morning Session: Neuroprotection and Drug Resistance
Chair: Dr Annamaria Vezzani, Milan, Italy
Professor Ley Sander, London, UK
Dr Çigdem Ozkara, Istanbul, Turkey
Professor Peter Wolf, Copenhagen, Denmark

9.00 Neuroprotection in Epilepsy
Dr Matthew Walker, London, UK

9.45 Is Neurogenesis Reparative after Status Epilepticus
Professor Jack Parent, Ann Arbor, USA

10.15 Endogenous Mechanisms of Neuroprotection
Professor Roger Simon, Portland, USA

10.45 Tea

11.15 Mechanisms of Drug Resistance in Status Epilepticus
Professor Wolfgang Löscher, Hannover, Germany

11.45 What is Animal Experimentation Telling us About New Drug Treatments of Status Epilepticus?
Professor Astrid Nehlig, Strasbourg, France

12.15 Lunch (and Poster Presentations)

continued
Saturday 14 April 2007 – Outcomes of SE continued

Afternoon Session: Outcome of Status Epilepticus and Guidelines

Chair: Dr Federico Vigevano, Rome, Italy
       Dr Martin Holtkamp, Berlin, Germany
       Dr Elizabeth Waterhouse, Richmond, USA

13.30 The Epidemiology of Convulsive and Nonconvulsive Status Epilepticus
       Dr Felix Rosenow, Marburg, Germany

14.00 Cognitive Outcome of Status Epilepticus in Adults
       Professor Christoph Helmstaedter, Bonn, Germany

14.30 Outcome of Status Epilepticus in Children
       Dr Alexis Arzimanoglou, Lyon, France

15.00 Tea

15.30 The Risk of Epilepsy after Status Epilepticus in Children and Adults
       Dr Hartmut Meierkord, Berlin, Germany

16.00 Out of Hospital Treatment of Status Epilepticus and Prolonged Seizures
       Professor Daniel Lowenstein, San Francisco, USA
       Professor James Cloyd, Minneapolis, USA

16.30 Treatment Guidelines in Status Epilepticus
       Dr Reetta Kälviäinen, Kuopio, Finland

17.00 Discussion
       Dr Elizabeth Waterhouse, Richmond, USA
       Professor Ley Sander, London, UK
       Dr Çigdem Özka, Istanbul, Turkey
       Dr Annamaria Vezzani, Milan, Italy
       Dr Federico Vigevano, Roma, Italy
       Dr Martin Holtkamp, Berlin, Germany
       Professor Peter Wolf, Copenhagen, Denmark

18.00 Close of Meeting
Sunday 15 April 2007 – Workshop to Develop Recommendations and Options for the Treatment of Status Epilepticus in Europe

8.30  
Registration and Coffee

9.00  
Workshop

Chairs:  Professor Simon Shorvon, London, UK  
Dr Eugen Trinka, Innsbruck, Austria  
Dr Matthew Walker, London, UK  
Dr Helen Cross, London, UK  
Professor Michel Baulac, Paris, France (Chair, ILAE Commission on European Affairs)

The purpose of the workshop is to devise a document listing recommendations and options for the optimal clinical management of status epilepticus in Europe. This document will be submitted to the ILAE Commission on European Affairs for adoption and dissemination.

The workshop will be open to all European clinical delegates attending the conference.

A draft preliminary document will be available to participants prior to the workshop. Included in this will be the results of a survey of contemporary European practice and a paper summarising the availability of individual IV therapies in Europe.

In the first part of the workshop, participants will be divided into five ‘working groups’. Each working group will consider one of the following five topics: (a) treatment of tonic clonic SE; (b) treatment of nonconvulsive SE; (c) treatment of EPC; (d) treatment of myoclonic SE in coma; (e) treatment of SE in specific childhood syndromes.

Following this, the groups will then meet together and present their conclusions, which will be debated by the whole assembly.

At the conclusion of the workshop, the core team will be tasked with producing a final document on the basis of the workshop deliberations.

Please could delegates wishing to attend the workshop indicate to which of the 5 working groups they would like to be attached.

12.00  END

This meeting is supported financially by the ILAE Commission on European Affairs, the UK Branch of the ILAE, and by an educational grant from UCB

Patrons of the meeting are: UCL Institute of Neurology, University of Innsbruck, the ILAE Commission on European Affairs, and the ILAE Commission on Therapeutic Strategies